Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-03.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 88 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 89 Clinical Implications of Different Thyroid-Stimulating Hormone (TSH) Reference Intervals between TSH Kits for the Management of Subclinical Hypothyroidism
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Endocrinol Metab > Volume 39(1); 2024 > Article
Letter
Thyroid Clinical Implications of Different Thyroid-Stimulating Hormone (TSH) Reference Intervals between TSH Kits for the Management of Subclinical Hypothyroidism
Won Sang Yooorcid
Endocrinology and Metabolism 2024;39(1):188-189.
DOI: https://doi.org/10.3803/EnM.2024.1934
Published online: February 5, 2024
  • 635 Views
  • 16 Download

Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea

Corresponding author: Won Sang Yoo. Department of Internal Medicine, Dankook University College of Medicine, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Korea Tel: +82-41-550-3063, Fax: +82-41-556-3256, E-mail: woxsos@gmail.com
• Received: January 14, 2024   • Accepted: January 17, 2024

Copyright © 2024 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

In 2023, the Korean Thyroid Association (KTA) released guidelines for the management of subclinical hypothyroidism [1]. The guidelines advise treatment for patients under 70 years old with thyroid-stimulating hormone (TSH) levels >10 mIU/L, while suggesting observation for those aged 70 and above [2]. Notably, the guidelines introduce a new upper limit for normal TSH levels of 6.8 mIU/L among Koreans. Previous guidelines have recommended that TSH reference ranges should be established based on regional research results, acknowledging that TSH standards might vary by region [3,4]. Accordingly, drawing upon data from the 2016 Korea National Health and Nutrition Examination Survey, the KTA defined the TSH reference range for Koreans as 0.6 to 6.8 mIU/L [5,6].
However, TSH measurements can vary significantly depending on the assay kit used. The KTA guidelines are based on a study using a single kit (Roche), but recognize the limitations in addressing inter-kit differences accurately [1,2]. To overcome this limitation, the KTA recently conducted a study that directly compared various TSH kits, including both chemiluminescence immunoassay (CLIA) and radioimmunoassay (RIA) methods, which are widely used in Korea [7]. Methodologically, this study was similar to projects such as the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) study, which compared reference ranges among different kits [8].
The study analyzed 100 residual blood samples, which had TSH levels ranging from 0 to 20 mIU/L, using eight different kits, including Roche(Basel, Switzerland), Abbott (Abbott Park, IL, USA), Beckman-CLIA (Brea, CA, USA), Siemens (Munich, Germany), Beckman-RIA (Brea), BRAHMS (Berlin, Germany), RIAKEY (Seoul, Korea), and Izotop (Budapest, Hungary) [7]. Correlation and regression analyses were performed on repeated measurements, providing slopes, intercepts, and 95% confidence intervals for the regression equations (Table 1).
Using Roche as the reference kit, the results for most kits demonstrated excellent correlations (R>0.99). However, the slopes varied between 0.75 and 1.06, indicating differences depending on the kit type. Consequently, the estimated values for the medical decision point of TSH corresponding to a level of 6.8 mIU/L measured using the Roche kit ranged between 5.2 and 7.4 mIU/L. For a level of 10.0 mIU/L using the Roche kit, the values for other kits ranged between 7.7 and 10.8 mIU/L, demonstrating considerable variation in the estimates across kits [7]. In general, the kit with the lowest TSH measurements was Abbott, while the kit with the highest measurements was Beckman-RIA. Previous studies, primarily comparing Roche and Abbott, consistently reported that Roche’s TSH measurements tended to be higher than Abbott’s, and this should be kept in mind [9,10].
In conclusion, it is of paramount importance for clinicians to maintain awareness of the TSH kit they employ and its characteristics compared to the Roche kit used in guideline development. Considering the pivotal role of TSH as a primary indicator in initiating and adjusting thyroid hormone therapy, widespread dissemination of this information is essential. This will help clinicians make well-informed decisions in the context of real-world clinical scenarios.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Table 1.
Estimation of Medical Decision Points Considering Differences between Roche and Other TSH Kits
TSH kit Medical decision point value (95% CI)
Linear correlation analysis with Roche
TSH 0.6 mIU/L TSH 6.8 mIU/L TSH 10.0 mIU/L R Slope Intercept
Abbott 0.46 (0.46 to 0.47) 5.2 (5.2 to 5.3) 7.7 (7.6 to 7.8) 0.997 0.75 (0.74 to 0.75) 0.11 (0.06 to 0.19)
Beckman-CLIA 0.58 (0.57 to 0.58) 6.5 (6.4 to 6.6) 9.7 (9.6 to 9.9) 0.993 0.94 (0.92 to 0.96) 0.083 (–0.044 to 0.21)
Siemens 0.61 (0.61 to 0.62) 6.9 (6.9 to 7.0) 10.2 (10.2 to 10.3) 0.999 1.03 (1.02 to 1.04) –0.06 (–0.13 to 0.00)
Beckman-RIA 0.65 (0.64 to 0.66) 7.4 (7.2 to 7.5) 10.8 (10.6 to 10.9) 0.992 1.06 (1.04 to 1.08) 0.09 (–0.06 to 0.24)
Brahms 0.50 (0.49 to 0.51) 5.7 (5.6 to 5.8) 8.3 (8.1 to 8.4) 0.992 0.86 (0.84 to 0.87) –0.08 (–0.20 to 0.04)
Riakey 0.47 (0.46 to 0.47) 5.3 (5.2 to 5.4) 7.9 (7.7 to 8.0) 0.994 0.88 (0.86 to 0.89) –0.39 (–0.50 to –0.29)
Izotop 0.53 (0.52 to 0.54) 6.0 (5.8 to 6.1) 8.9 (8.8 to 8.9) 0.999 0.89 (0.88 to 0.90) 0.06 (0.01 to 0.12)

TSH, thyroid stimulating hormone; CI, confidence interval; CLIA, chemiluminescence immunoassay; RIA, radioimmunoassay.

  • 1. Ku EJ, Yoo WS, Chung HK. Management of subclinical hypothyroidism: a focus on proven health effects in the 2023 Korean Thyroid Association Guidelines. Endocrinol Metab (Seoul) 2023;38:381–91.ArticlePubMedPMCPDF
  • 2. Chung HK, Ku EJ, Yoo WS, Kang YE, Kim KJ, Kim BH, et al. 2023 Korean Thyroid Association management guidelines for patients with subclinical hypothyroidism. Int J Thyroidol 2023;16:32–50.Article
  • 3. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J 2013;2:215–28.ArticlePubMedPMC
  • 4. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014;24:1670–751.ArticlePubMedPMC
  • 5. Kim WG, Kim WB, Woo G, Kim H, Cho Y, Kim TY, et al. Thyroid stimulating hormone reference range and prevalence of thyroid dysfunction in the Korean population: Korea National Health and Nutrition Examination Survey 2013 to 2015. Endocrinol Metab (Seoul) 2017;32:106–14.PubMedPMC
  • 6. Park SY, Kim HI, Oh HK, Kim TH, Jang HW, Chung JH, et al. Age- and gender-specific reference intervals of TSH and free T4 in an iodine-replete area: data from Korean National Health and Nutrition Examination Survey IV (2013-2015). PLoS One 2018;13:e0190738.ArticlePubMedPMC
  • 7. Yoo WS, Kim S, Park YJ, Song SH, Lee K, Lee EK, et al. Comparison of thyroid-stimulating hormone results from eight different reagents and assay-specific Korean reference interval for subclinical hypothyroidism treatment. Int J Thyroidol 2023;16:166–74.Article
  • 8. Higgins V, Chan MK, Nieuwesteeg M, Hoffman BR, Bromberg IL, Gornall D, et al. Transference of CALIPER pediatric reference intervals to biochemical assays on the Roche cobas 6000 and the Roche Modular P. Clin Biochem 2016;49:139–49.ArticlePubMed
  • 9. Razvi S, Jabbar A, Addison C, Vernazza J, Syed A, Soran H, et al. Variation in the reference range limits of thyroid function tests and association with the prevalence of levothyroxine treatment. Eur J Endocrinol 2023;188:lvad016.ArticlePubMedPDF
  • 10. Ursem SR, Boelen A, Hillebrand JJ, den Elzen WP, Heijboer AC. How low can we (reliably) go?: a method comparison of thyroid-stimulating hormone assays with a focus on low concentrations. Eur Thyroid J 2023;12:e230123.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  


      Endocrinol Metab : Endocrinology and Metabolism